These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 31702819

  • 1. Multidrug resistant gastrointestinal stromal tumor with multiple metastases to the skin and subcutaneous soft tissue: A case report and review of literature.
    Aickara DJ, McBride J, Morrison B, Romanelli P.
    J Cutan Pathol; 2020 Apr; 47(4):398-401. PubMed ID: 31702819
    [Abstract] [Full Text] [Related]

  • 2. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
    Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.
    Br J Cancer; 2019 Mar; 120(6):612-620. PubMed ID: 30792533
    [Abstract] [Full Text] [Related]

  • 3. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.
    Clin Cancer Res; 2019 Dec 15; 25(24):7287-7293. PubMed ID: 31471313
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour.
    Yang W, Li K, Yu J, Shou C, Zhang Q, Hong Y, Sun J, Yu H, Gao Y, Shen Q, Zhao Z, Zheng S.
    Scand J Gastroenterol; 2018 Dec 15; 53(10-11):1328-1334. PubMed ID: 30346846
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T, Doi T, Naito Y.
    Expert Opin Pharmacother; 2014 Oct 15; 15(14):1979-89. PubMed ID: 24990162
    [Abstract] [Full Text] [Related]

  • 6. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL, Fletcher CD.
    Hum Pathol; 2007 May 15; 38(5):679-87. PubMed ID: 17437861
    [Abstract] [Full Text] [Related]

  • 7. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J, Wang S, Wang R, Wang SY, Han Q, Xu HT, Yang P, Liu Y.
    Pathol Oncol Res; 2020 Jan 15; 26(1):91-100. PubMed ID: 31758409
    [Abstract] [Full Text] [Related]

  • 8. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression.
    Tang CM, Lee TE, Syed SA, Burgoyne AM, Leonard SY, Gao F, Chan JC, Shi E, Chmielecki J, Morosini D, Wang K, Ross JS, Kendrick ML, Bardsley MR, Siena M, Mao J, Harismendy O, Ordog T, Sicklick JK.
    Oncotarget; 2016 Nov 29; 7(48):78226-78241. PubMed ID: 27793025
    [Abstract] [Full Text] [Related]

  • 9. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 29; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 10. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
    Kondo T.
    Adv Exp Med Biol; 2016 Jan 29; 926():139-151. PubMed ID: 27686810
    [Abstract] [Full Text] [Related]

  • 11. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
    Hsueh YS, Chang HH, Shan YS, Sun HS, Fletcher JA, Li CF, Chen LT.
    Oncogene; 2019 Sep 29; 38(38):6550-6565. PubMed ID: 31363162
    [Abstract] [Full Text] [Related]

  • 12. Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
    Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE.
    Cancer Res; 2019 Mar 01; 79(5):994-1009. PubMed ID: 30630822
    [Abstract] [Full Text] [Related]

  • 13. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
    Lai S, Wang G, Cao X, Luo X, Wang G, Xia X, Hu J, Wang J.
    Oncotarget; 2016 Jan 12; 7(2):1367-79. PubMed ID: 26587973
    [Abstract] [Full Text] [Related]

  • 14. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB.
    Cancer Res; 2017 Sep 15; 77(18):5107-5117. PubMed ID: 28760855
    [Abstract] [Full Text] [Related]

  • 15. Targeting the translational machinery in gastrointestinal stromal tumors (GIST): a new therapeutic vulnerability.
    Lee DM, Sun A, Patil SS, Liu L, Rao AV, Trent PT, Ali AA, Liu C, Rausch JL, Presutti LD, Kaczorowski A, Schneider F, Amankulor NM, Shuda M, Duensing A.
    Sci Rep; 2022 May 18; 12(1):8275. PubMed ID: 35585158
    [Abstract] [Full Text] [Related]

  • 16. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 18; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 17. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
    Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schöffski P, Mehren MV, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC.
    Future Oncol; 2020 Jan 18; 16(1):4251-4264. PubMed ID: 31755321
    [Abstract] [Full Text] [Related]

  • 18. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
    Rausch JL, Boichuk S, Ali AA, Patil SS, Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, Kuan SF, Duensing A.
    Oncotarget; 2017 Jan 17; 8(3):4471-4483. PubMed ID: 27965460
    [Abstract] [Full Text] [Related]

  • 19. Translational insights into gastrointestinal stromal tumor and current clinical advances.
    Hemming ML, Heinrich MC, Bauer S, George S.
    Ann Oncol; 2018 Oct 01; 29(10):2037-2045. PubMed ID: 30101284
    [Abstract] [Full Text] [Related]

  • 20. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.
    Ann Oncol; 2016 Sep 01; 27(9):1794-9. PubMed ID: 27371698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.